
    
      This is a single-arm and open-label study. Approximately 10-12 patients will be enrolled per
      each genetic alterration group in the study. ATG-008 is the monotherapy for advanced solid
      tumors with 30mg QD. The clinical efficacy, safety and tolerability of ATG-008 will be
      evaluated. Addtionalal dose levels may apply after the efficacy/safety and tolerabitly of
      30mg QD has been accessed by Sponosor and study steering committee.
    
  